Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design

• Main Authors: Annunziata D'Ercole (Author), Silvia Nistri (Author), Lorenzo Pacini (Author), Alfonso Carotenuto (Author), Federica Santoro (Author), Anna Maria Papini (Author), Ross A. D. Bathgate (Author), Daniele Bani (Author), Paolo Rovero (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The peptide hormone relaxin (RLX), also available as clinical-grade recombinant protein (serelaxin), holds great promise as a cardiovascular and anti-fibrotic agent but is limited by the pharmacokinetic issues common to all peptide drugs. In this study, by a computational modelling chemistry approac...